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BASIC SCIENCE STUDIES
From the Midwestern Vascular Surgical Society
The implantation of a prosthetic vascular graft
initiates a host response that results in the relative
incorporation of the graft into the native vasculature.
Included in this response is the local production of
cytokines. Early perfusion studies have revealed
markedly higher mitogenic activity for smooth mus-
cle cells (SMCs) in perfusates of the graft than in the
native aorta.1 Since that time, several studies have
shown increased platelet-derived growth factor
(PDGF) production with graft segments.2-6 PDGF
secretion is elevated early after implantation and may
be a result of the release of PDGF from platelets and
leukocytes during deposition onto the graft surface.
In addition, PDGF production levels have been
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shown to remain elevated in grafts studied as long as
2 years after implantation.5 The cells of the neointi-
ma, specifically the SMCs, are responsible for much
of the chronically increased PDGF production.7
The local production of PDGF may modulate the
response of graft SMCs through autocrine and
paracrine pathways. Indeed, chronic autostimulation
of graft SMCs may play a key role in the accumula-
tion of cells seen in intimal hyperplasia. Coexpression
of both PDGF and PDGF receptor messenger RNA
(mRNA) has been shown in the neointima of pros-
thetic vascular grafts.8 The demonstration of PDGF
receptor mRNA, and even protein, however, is not
always associated with the ability of SMCs to respond
to PDGF.9 This study was undertaken to determine
whether graft SMCs are capable of responding to
PDGF and to compare the proliferative response of
graft SMCs with the response of native aortic SMCs.
MATERIALS AND METHODS
Graft implantation and removal. Double
velour–knitted Dacron grafts with 6-mm internal
diameters (Meadox Medicals Inc, Oakland, NJ) or
expanded polytetraflouroethylene (ePTFE) grafts with
8-mm internal diameters (W.L. Gore & Assoc, Elkton,
Md) that were 20 to 22 cm in length were implanted
in the thoracoabdominal position in adult female bea-
gles as described previously.7 The protocol for the ani-
mal studies was approved by the Institutional Review
Board. Care complied with the Guide for the Care
and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council. Washington:
National Academy Press, 1996).
At the time of graft removal, the grafts and
native vessels were carefully isolated, flushed with
tissue culture medium (M199, Sigma Chemical Co,
St Louis, Mo), and excised. The graft and aorta were
opened and divided, which yielded anastomotic and
midgraft segments and native aortas proximal and
distal to the graft implantation site. The anastomot-
ic segments consisted of the graft within 2 cm of the
anastomosis and the aorta within 1 cm of the anas-
tomosis. The remainder of the graft was considered
midgraft. The proximal aorta consisted of the
ascending aorta, the arch, and the descending aorta
to 1 cm proximal to the anastomosis. The distal
aorta was taken from 1 cm distal to the anastomosis
to the aortic trifurcation. Fibrous tissue on the graft
exterior was carefully removed from the graft. These
segments then were pinned on Sylgard 184 elas-
tomer discs (Dow Corning, Corp, Midland, Mich)
and readied for cell harvest in M-199 medium.
Cell harvest and culture conditions. Endoth-
elial cells were removed from the segments with a
rounded spatula after incubation in M199 medium
that contained 630 units/mL collagenase A
(Boehringer Mannheim Biochemicals, Indianapolis,
Ind) for 10 minutes at 37°C in a 5% CO2 atmosphere.
The medial layer of the aorta then was mechanically
harvested, and the media and the graft were divided
into 2 · 2–mm2 pieces. These pieces were incubated
for 2 hours in M199 medium that contained 15
units/mL elastase type III (Sigma), 170 units/mL
collagenase A, 2 mg/mL crystalline bovine serum
albumin (BSA, Boehringer Mannheim), and 0.375
mg/mL soy bean trypsin inhibitor (Boehringer
Mannheim). The SMCs then were collected by means
of centrifugation at 300g for 5 minutes and resus-
pended in M199 medium. The identity and homo-
geneity of the SMC population was confirmed
immunohistochemically with antibody to SMC a -
actin (Sigma). The SMCs were plated in serum-coated
tissue wells and grown in M199 medium with 20%
fetal bovine serum (FBS, Hyclone Laboratories,
Logan, Utah). The SMCs in primary culture were
used for growth curve kinetics experiments. For the
remainder of the experiments, the SMCs were grown
to confluence, passaged with trypsinization and sub-
culturing, and used in either passage one or two.
Smooth muscle cell proliferation assays. SMC
proliferation was assessed with the following 
two methods: incorporation of [3H]thymidine and
direct cell counting. For [3H]thymidine uptake stud-
ies, 1.85 · 104 Bq m Ci of [3H]thymidine (ICN
Biomedicals, Irvine, Calif) was added to each well
after 18 hours of incubation in the various conditions
and the incubation was continued for another 6
hours. At the end of the 24-hour incubation, the cells
were washed twice with serum-free medium. DNA
was precipitated with 0.5% trichloroacetic acid
(Sigma), and the precipitate was solubilized in 0.75
mL of 0.25 N NaOH. A 0.5-mL aliquot then was
transferred to a scintillation vial, the pH was neutral-
ized with 50 m L of 6 N HCl, and 5 mL of ScintiVerse
(Fisher Scientific, Irvine, Calif) was added. The sam-
ple was analyzed in a liquid scintillation counter.
For the assessment of proliferation with direct cell
counts, the SMCs were rinsed with PBS, removed
from the plates with incubation with trypsin, and then
vortexed to eliminate clumping. Two aliquots from
each well were counted with a hemocytometer, and
the average was used. All the measurements were per-
formed in duplicate wells.
Receptor binding studies. PDGF binding stud-
ies then were performed with Ham’s F12/Dulbecco’s
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Modified Eagle’s (DME) high glucose medium
(Irvine Scientific, Santa Ana, Calif) with 25 mmol/L
of N-2-hydroxyethylpiperazine-N-2-ethanesulfonic
acid (Sigma) plus 2% BSA as previously described.10
125I-labeled PDGF-BB (25 fmol; Amersham Phar-
macia Biotech, Little Chalfont, United Kingdom)
were added along with unlabeled ligand over a con-
centration range of 32 pmol/L to 4.1 nmol/L. After
a 4-hour incubation at 4°C, the cells were washed four
times at 4°C with PBS that contained 1 mmol/L
CaCl2 and 1% BSA. The cells then were solubilized in
1% octylphenoxypolyethoxyethanol X-100 (Sigma)
with 1% BSA buffer and analyzed in a gamma counter.
Radioactive counts were normalized for cell count
after the background was subtracted. Maximal binding
(Bmax) and dissociation constant (Kd) were derived
with a nonlinear least squares curve fitting program
that fit the data to a linear low-affinity non-specific
binding component and a non-linear high-affinity spe-
cific binding component.
Statistical analysis. The data were expressed as
the mean ± the standard error of the mean. For the
proliferation experiments, the data were compared
with analysis of variance or with Student paired t
test. The values for Bmax and Kd for the various seg-
ments then were compared with analysis of variance.
Statistical significance was assumed if the P value was
less than .05.
RESULTS
Smooth muscle cell growth curves. To study
the initial rates of proliferation in culture, the growth
curves were evaluated with primary aortic and graft
SMCs from five dogs with Dacron grafts that were
implanted for 16 to 22 weeks (Fig 1). In all the
experiments, the onset of proliferation for the aortic
cells lagged behind the onset of the graft SMCs by
about 2 days. Once proliferation began, the rate of
cell doubling was similar for aortic and graft SMCs.
Proliferative response to platelet-derived
growth factor. For the determination of the effect
of PDGF on SMC proliferation, the graft and aortic
SMCs were harvested from seven dogs with grafts
(four Dacron and three ePTFE) that were implanted
for 16 to 26 weeks. Early passage cells were made
quiescent and then were incubated with varying con-
centrations of PDGF-AB (Upstate Biotechnologies
Inc, Lake Placid NY), and the proliferative response
was determined by means of [3H]thymidine uptake
and cell count. Both the graft and the aortic SMCs
exhibited a dose-related increase in [3H]thymidine
uptake after exposure to PDGF as compared with the
control in 0.5% FBS (Fig 2). The increase that was
seen at the maximum dose of PDGF (10 ng/mL)
relative to control was similar in the SMCs from
proximal and distal aortas, 11.8 ± 3.0–fold and 10.2
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Fig 1. Growth of graft and aortic smooth muscle cells
(SMCs) in primary culture. Equal numbers of SMCs har-
vested from aortas and Dacron grafts were plated in M199
medium (Sigma Chemical Company, St Louis, Mo) and
20% fetal bovine serum. Cell counts were performed after
1, 2, 4, 6, and 8 days. SMCs from five dogs were studied,
and representative growth curve expressed as log2 of the
cell count at time x/cell count at baseline is depicted.
Fig 2. Uptake of [3H]thymidine in response to platelet-
derived growth factor (PDGF). Early passage graft and
aortic smooth muscle cells were plated at a density of
20,000 cells/cm2 in M199 medium (Sigma Chemical
Company, St Louis, Mo) that contained 20% fetal bovine
serum (FBS) and were allowed to attach overnight.
Smooth muscle cells were made quiescent in medium with
FBS 0.5% for 48 hours, and then were incubated in
DME/F12 (Irvine Scientific, Santa Ana, Calif) that con-
tained 0.5% FBS and varying concentrations of PDGF-AB.
Proliferative response, as determined with [3H]thymidine
uptake during hours 18 and 24 of the incubation, is
depicted. In each segment, there was an increase in PDGF
(10 ng/mL) group as compared with control (P < .05,
with Student paired t test). Relative increase was decreased
in graft as compared with proximal and distal aortas (P <
.05, with analysis of variance).
± 1.9–fold, respectively (P = NS). The relative
increase seen in graft SMCs was 1.7 ± 0.1–fold,
which was significantly less than that of both the
proximal and the distal aortic SMCs (P < .05). The
blunted response was seen in SMCs from both
Dacron and ePTFE grafts, with relative increases of
1.9 ± 0.1 and 1.5 ± 0.1, respectively.
Similar results were obtained when proliferation
was measured with cell counts (Fig 3). After expo-
sure to PDGF (10 ng/mL) for 72 hours, there was
a 2.8 ± 0.5–fold and a 2.9 ± 0.8–fold increase in cell
number over baseline (at the start of the PDGF
incubation period) in the proximal and distal aortic
SMCs, respectively. These increases were significant-
ly greater than the 1.1 ± 0.1–fold increase that was
seen in the graft SMCs (P < .05). Again, the blunt-
ed response was seen in the SMCs from both the
Dacron and the ePTFE grafts, with relative increas-
es of 1.1 ± 0.1 and 1.1 ± 0.2, respectively. Of note,
graft SMCs consistently showed lower attachment
than did aortic SMCs, and there was a decrease in
cell number after exposure to control medium for 72
hours as compared with baseline (P < .05). This
decrease was not observed in the aortic cells and pre-
sumably represents cell detachment or death.
The proliferative response of SMCs from anasto-
motic segments in this same group was compared
with the responses of mid graft and aortic SMCs.
The anastomotic segments consisted of 2 cm of graft
and 1 cm of adjacent aorta. With maximal stimula-
tion with PDGF (10 ng/mL), the SMCs from the
proximal anastomotic segment exhibited a 4.2 ±
2–fold increase in [3H]thymidine uptake and a 1.2 ±
0.3–fold increase in cell count, and the SMCs from
the distal anastomotic segment exhibited a 2.3 ±
0.4–fold increase in [3H]thymidine uptake and a 1.1
± 0.2–fold increase in cell count. These results, par-
ticularly the [3H]thymidine uptake results, are inter-
mediate to those of the midgraft and aortic SMCs,
which is probably a reflection of the fact that these
cells represented a mixture of graft and aortic SMCs.
To determine whether the graft SMC response
to PDGF varied with the time of graft implantation,
similar studies were conducted with SMCs harvested
from Dacron grafts that were implanted for 4, 57,
and 77 weeks. Like the SMCs from 20-week grafts,
the relative increase in cell number with maximal
stimulation with PDGF (10 ng/mL) was diminished
in these graft SMCs as compared with their aortic
counterparts (Fig 4). Similar findings were seen with
[3H]thymidine uptake (data not shown). Thus, it
appears that the blunted response of graft SMCs to
PDGF is present throughout this extended time
course of graft implantation.
Receptor binding characteristics. To deter-
mine whether the blunted response of the graft
SMCs to PDGF was a result of the alteration in
PDGF receptor number or affinity, PDGF receptor
binding studies were performed with radio-labeled
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Fig 3. Cell count in response to platelet-derived growth fac-
tor (PDGF). Early passage graft and aortic smooth muscle
cells were plated overnight in M199 medium (Sigma
Chemical Company, St Louis, Mo) with 20% fetal bovine
serum and then were made quiescent for 48 hours. Smooth
muscle cells then were incubated in DME/F12 (Irvine
Scientific, Santa Ana, Calif) that contained 0.5% fetal bovine
serum and varying concentrations of PDGF (0, 0.1, 1, and
10 ng/mL). Cell number was determined at baseline
(beginning of incubation) and after 72 hours of exposure to
medium with and without PDGF. In each segment, there
was an increase in the PDGF (10 ng/mL) group as com-
pared with control (P < .05, with Student paired t test).
Relative increase was decreased in graft as compared with
proximal and distal aortas (P < .05, with analysis of variance).
Fig 4. Response to platelet-derived growth factor (10
ng/mL) as function of duration of graft implantation. Data
from proximal and distal aortas are combined. Note that at
each time point relative increase in graft smooth muscle
cells was less than that of aortic smooth muscle cells.
PDGF-BB because it binds to all PDGF receptor
dimers. The aortic and graft SMCs from five dogs
with Dacron grafts that were implanted for 16 to 22
weeks were studied. Bmax, which represents the fem-
tomole of PDGF receptors available for binding per
million cells, was greater in both proximal and distal
aortic SMCs than in graft SMCs, 419 ± 147 and 387
± 112 versus 185 ± 70, respectively (P < .05; Fig 5).
Kd was measured at 107 ± 29 pmol/L, 72 ± 19
pmol/L, and 84 ± 18 pmol/L for the proximal
aorta, graft, and distal aorta, respectively, and did
not differ significantly. Thus, the number of recep-
tors available to bind exogenous PDGF was signifi-
cantly decreased in graft SMCs as compared with
aortic SMCs, but the affinity of binding was similar
in both types of SMCs.
DISCUSSION
Altered SMC proliferation is considered an
important component of most vascular lesions,
including intimal hyperplasia of prosthetic grafts.
Most previous investigations that characterized the
proliferative response of lesional SMCs have used
arterial injury models. With such a model, Grunwald
and Haudenschild11 showed that SMCs that were
harvested from balloon-injured arteries proliferated
sooner than did SMCs from control explants. The
growth curves in our study indicated that graft
SMCs behave similarly and suggested that the graft
SMCs exist in a proliferative state in vivo. In support
of this idea is the work of Clowes et al12 who
demonstrated the continued proliferation of SMCs
at the anastomoses and under the advancing
endothelium on PTFE grafts at 6 and 12 months
after implantation in baboons.
The factors responsible for the increased SMC
proliferation seen in vascular lesions are not com-
pletely understood. Of note, however, is that the
growth of SMCs from injured arteries occurs even in
serum-free medium,11 which suggests that these
SMCs may be responding in an autocrine or
paracrine fashion to the mitogens that they produce.
SMCs on prosthetic grafts produce mitogens,
including PDGF,7 and our study now shows that
these SMCs can respond to PDGF, which suggests
that autocrine stimulation is posslble. Other factors,
however, may also contribute to SMC proliferation
in grafts.
The magnitude of the proliferative response of
graft SMCs to PDGF is diminished as compared with
the response of aortic SMCs and similar to the
response of SMCs from arterial injury models.
Walker et al13 found a diminished response to PDGF
in intimal SMCs from injured arteries. With a similar
model, Majack et al9 not only found a 20-fold
decrease in the proliferative response to PDGF but
also found decreased responsiveness to other growth
factors. The decreased responsiveness to mitogenic
stimuli is a characteristic that is common to an imma-
ture SMC phenotype,14 and this phenotype is likely
re-expressed after an arterial injury. Preliminary data
from our laboratory (not shown) suggest that graft
SMCs may also have a blunted proliferative response
to basic fibroblast growth factor and FBS, which
supports the idea that the immature phenotype is
also re-expressed during graft healing.
The mechanism responsible for the blunted pro-
liferative response remains unclear. Our study sug-
gests that alterations in receptor binding, specifically
a decrease in the number of receptors available for
binding with little change in affinity, play a role.
Similarly, Walker et al13 found decreased PDGF
binding to intimal SMCs from injured arteries. This
decrease may represent the downregulation of
receptors, as can be seen in cultured SMCs with
chronic exposure to PDGF.15 With immunohisto-
chemical analysis, however, Kraiss et al8 demonstrat-
ed more PDGF receptor-b protein in the neointima
of PTFE grafts implanted in baboons than in healthy
aorta. Likewise, Majack et al,9 despite demonstrat-
ing a marked decrease in the PDGF responsiveness
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Fig 5. Binding characteristics of platelet-derived growth
factor (PDGF)–BB. With 24-well plates, passage one
smooth muscle cells were plated at density of 50,000
cells/cm2 in M199 medium (Sigma Chemical Company, St
Louis, Mo) that contained fetal bovine serum 20% and then
were made quiescent in M199 medium with fetal bovine
serum 0.5% for 48 hours. Cell counts were performed, and
PDGF receptor binding then was determined with 125I-
labeled PDGF-BB. Maximal binding (femtomole/million
cells) was decreased in graft as compared with proximal and
distal aortas (P < .05, with analysis of variance). Dissociation
constant (picomolar) did not differ significantly.
of intimal SMCs from injured arteries, found abun-
dant PDGF receptor mRNA and protein in these
same cells. It is possible, then, that the receptors
were present but unavailable for binding of exoge-
nous PDGF, perhaps as a result of occupation by
endogenously produced PDGF. If this was the case,
however, the basal proliferation should have been
higher in passaged graft versus aortic SMCs, unless
growth signaling pathways were blocked distal to
the bound receptor. Majack et al9 suggested that this
“mitogenic block” may be part of the immature
SMC phenotype.
The results of the present study provide insight
into the normal graft healing response. The mecha-
nisms responsible for the development of anasto-
motic intimal hyperplasia remain less clear. In the
study, we examined a 3-cm segment that contained
the anastomosis. Although these cells should be
from the area of an anastomotic hyperplastic lesion,
the data suggest that they are a mixture of graft and
aortic cells. The anastomosis is an interface between
PDGF-producing graft SMCs and PDGF-responsive
arterial SMCs. It is interesting to postulate that the
proximity of these different SMC phenotypes con-
tributes to the development of intimal hyperplasia in
these regions. In the midgraft, on the other hand,
SMCs are less responsive and excessive accumulation
does not occur despite chronic exposure to high lev-
els of PDGF. The study, of course, does not address
a multitude of other factors, including the effects of
PDGF on SMC migration or collagen production,
which may be important in graft healing or the
development of intimal hyperplasia.
In summary, we have shown that, in a canine
model, SMCs harvested from the graft enter log
phase growth early, which suggests that they are in
a proliferative state in vivo, unlike the quiescent
native aortic SMCs. Furthermore, graft SMCs pro-
liferate in response to PDGF, but the response is
blunted as compared with the response of aortic
SMCs. The lower proliferative response appears to
be caused by decreased PDGF receptor binding,
which suggests that during normal graft healing
there is a negative feedback to prevent continued
SMC proliferation. The effect of the elevated PDGF
production on adjacent arterial SMCs and its role in
stimulating anastomotic intimal hyperplasia remain
speculative.
We thank Meadox Medicals Inc and W.L. Gore &
Associates for the donations of the grafts.
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Dr John Hoch (Madison, Wis). I am not too familiar
with your program’s work with this model. I assume you
have done in vivo studies looking at cell proliferation in
this neointima from which you are harvesting your cells,
with either 5-bromo-2¢- deoxyuridine or proliferating cell
nuclear antigen. Your hypothesis is that these cells are in a
proliferative state, so I assume you have looked at that. An
alternative hypothesis is that these cells are not actually
smooth muscle cells, but myofibroblasts. This could
explain their activity in culture being different than the
native arterial wall smooth muscle cells. Have you taken
these harvested graft cells and looked at them via trans-
mission electron microscopy and tried to determine ultra-
structurally whether these are smooth muscle cells or in
fact myofibroblasts? 
Dr David J. Minion. Most of the early work regarding
proliferation in the neointima was performed by Clowes et
al, who found that there was continued proliferation in
grafts up to 12 months after implantation. Interestingly,
accumulation of smooth muscle cells stopped at 3 months.
They postulated that cell proliferation was being matched
by cell death. I think our results regarding cell counts cor-
relate well with these findings in that we found that cell
loss at low concentrations of PDGF that was nearly as
great as cell proliferation at higher concentrations of
PDGF.
Regarding the identity of these cells or the classifica-
tion of these cells, we have done ultrastructural studies,
and they have the characteristics of smooth muscle cells in
a secretory state. We also routinely stain these cells for a -
actin, and they are positive. Whether these cells are
smooth muscle cells or myofibroblasts may be semantics,
and I am not sure that we have answered that question.
Dr Robert Thompson (St Louis, Mo). I am interest-
ed in the cells that exhibit the decreased proliferative rates
in vitro and the decreased receptor population in those
cells. Is this a phenomenon in the decreased growth rate
of cell death balancing or exceeding growth, or is it senes-
cence? And have you taken these cells out in further pas-
sage to see if they ultimately become senescent in a short-
er number of passages than the control cells?
Dr Minion. We have taken them out to further pas-
sages. It does become more difficult to grow these cells at
later passages than the aortic counterparts. The reason for
that may be because of their decreased response to mito-
gens. We can grow them, but clearly there are some other
phenotypic changes that occur. These cells may be more
prone to senescence or cell death, but we have not
addressed that directly.
Dr Thompson. Senescence is a phenotypic change that
becomes a relatively permanent change in that population.
It may actually be induced by a period of excessive prolif-
eration and then they reach their proliferative potential and
exhibit other characteristics such as receptor down regula-
tion. Those changes may not be correctable in the cells, so
that biology is a very interesting area of investigation.
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DISCUSSION
